+39,840.3%
COHR vs GSK
+1,644.3%
+38,196.0%
-80.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -12.9% | -0.1% | -12.8% | -12.9% |
| 7D | -14.2% | -5.3% | -8.8% | -13.2% |
| 30D | -21.2% | -3.7% | -17.5% | -20.7% |
| 3M | -35.4% | -7.3% | -28.2% | -34.8% |
| 6M | -47.8% | -4.2% | -43.5% | -48.0% |
| YTD | +1.4% | +0.9% | +0.6% | -0.5% |
| 1Y | +38.1% | +7.3% | +30.8% | +33.3% |
| 3Y | +414.3% | +52.7% | +361.6% | +340.7% |
| 5Y | +192.2% | +40.1% | +152.1% | +153.2% |
| 10Y | +509.8% | +98.7% | +411.1% | +384.2% |
| All | +39,840.3% | +1,644.3% | +38,196.0% | +20,617.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling